PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1072844
PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1072844
Digital PCR (dPCR) and Real-time PCR (qPCR) Market Size, Share & Trends Analysis By Product & service, By Application, By End-User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market projected to be worth USD 11.39 billion by 2030.
According to SPER Market Research, the Digital PCR (dPCR) and Real-time PCR (qPCR) Market estimated to reach USD 11.39 billion by 2030 with a CAGR of 8.8%.
The key fuels for the market escalation are; advanced PCR technologies, growing investments, increasing genetic as well as targeted infectious disease, raising the exploit of biomarkers profiling in the disease diagnosis, and the booming Human Genome project.
Impact of COVID-19 on the Digital PCR (dPCR) and Real-time PCR (qPCR) Market
The COVID-19 outbreak has mainly impacted to the healthcare industry; diagnostic industry is one of them. There is a positive impact in the PCR industries. Digital PCR (dPCR) and Real-time PCR (qPCR) has the importance in the diagnostic and drug discovery. The focus of the companies is to produce digital PCR kits for the diagnosis of the infection.
Scope of the report:
- Market size available for years: 2019-2030
- Base year considered: 2021
- Forecast period: 2022-2030
Segments covered By Product & Service, By Application, By End-User, By Region.
Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East, Africa
Companies Covered: Abbott Laboratories, Agilent Technologies, Analytik Jena AG, Becton, Dikinson and Compan, bioMerieux SA, Bioneer, Bio-Rad Laboratories Inc.Dan, aher Corporation, ELITech Group, Enzo Life Sciences, Inc., Eppendorf, F. Hoffmann-La Roche, Ltd., Fluidigm Corporation, Merck KGaA, Meridian Bioscience, Promega Corporation, QIAGEN N.V., Quidel Corporation, Thermo Fisher Scientific, Takara Bio
Driver: growing occurrence of target infectious diseases and genetic disorders
Rising incidence of target infectious diseases and genetic disorders, technological advancements in PCR technologies, increasing investments, funds, and grants, increasing use of biomarker profiling for disease diagnostics, successful completion of the Human Genome Project; are the key drives of the escalation of the market.
Restraint: High device costs coupled with dPCR
Technical limitations of qPCR and dPCR techniques, costly device coupled with dPCR; can resist the escalation of the market.
Opportunity: rising market penetration in emerging countries
Growing market penetration in emerging countries, shift from plant-derived to genome-based drug discovery; offers enormous opportunities to the players in the market.
Challenges:
Adoption and implementation of MIQE guidelines, is the challenge to the market expansion.
Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By Product & Service:
Based on the Product and Service, Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market is segmended as; qPCR Products & Services (qPCR Reagents and Consumables, qPCR Instruments, qPCR Software and Services), dPCR Products & Services (dPCR Instruments, dPCR Reagents and Consumables, dPCR Software and Services).
Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By Application:
Based on the Application, Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market is segmended as; qPCR Applications (Clinical Applications, Forensic Applications, Research Applications), dPCR Applications (Clinical Applications, Research Applications, Forensic Applications).
Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By End-User:
Based on the End-User, Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market is segmended as; qPCR End User (Clinical Research Organizations, Forensic Laboratories, Hospitals and Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Research Laboratories and Academic Institutes), qPCR End User (Clinical Research Organizations, Forensic Laboratories, Hospitals and Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Research Laboratories and Academic Institutes).
Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By Region:
North America, dominates the principal share of this market; and this is because of accessibility to research & development funding, growing acceptance of innovative and novel genomic analysis, escalating use of PCR techniques in the clinical diagnostics, forensics, and commercialization of qPCR/dPCR products.
Table of Contents
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1 Research data source
- 2.1.1 Secondary data
- 2.1.2 Primary data
- 2.1.3 SPER's internal database
- 2.1.4 Premium insight from KOL's
- 2.2 Market size estimation
- 2.2.1 Top-down and Bottom-up approach
- 2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1 Drivers
- 4.1.2 Restraints
- 4.1.3 Opportunities
- 4.1.4 Challenges
- 4.2. COVID-19 Impacts of the Digital PCR (dPCR) and Real-time PCR (qPCR) Market
5. Market variables and outlook
- 5.1. SWOT analysis
- 5.1.1 Strengths
- 5.1.2 Weaknesses
- 5.1.3 Opportunities
- 5.1.4 Threats
- 5.2. PESTEL analysis
- 5.2.1 Political landscape
- 5.2.2 Economic landscape
- 5.2.3 Social landscape
- 5.2.4 Technological landscape
- 5.2.5 Environmental landscape
- 5.2.6 Legal landscape
- 5.3. PORTER'S five forces analysis
- 5.3.1 Bargaining power of suppliers
- 5.3.2 Bargaining power of Buyers
- 5.3.3 Threat of Substitute
- 5.3.4 Threat of new entrant
- 5.3.5 Competitive rivalry
- 5.4. Heat map analysis
6. Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By Product & Service, 2019-2030 (USD Million)
- 6.1. qPCR Products & Services
- 6.1.1. qPCR Reagents and Consumables
- 6.1.2. qPCR Instruments
- 6.1.3. qPCR Software and Services
- 6.2. dPCR Products & Services
- 6.2.1. dPCR Instruments
- 6.2.2. dPCR Reagents and Consumables
- 6.2.3. dPCR Software and Services
7. Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By Application, 2019-2030 (USD Million)
- 7.1. qPCR Applications
- 7.1.1. Clinical Applications
- 7.1.2. Forensic Applications
- 7.1.3. Research Applications
- 7.2. dPCR Applications
- 7.2.1. Clinical Applications
- 7.2.2. Research Applications
- 7.2.3. Forensic Applications
8. Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By End-User, 2019-2030 (USD Million)
- 8.1. dPCR End User
- 8.1.1. Clinical Research Organizations
- 8.1.2. Forensic Laboratories
- 8.1.3. Hospitals and Diagnostic Centers
- 8.1.4. Pharmaceutical and Biotechnology Companies
- 8.1.5. Research Laboratories and Academic Institutes
- 8.2. qPCR End User
- 8.2.1. Clinical Research Organizations
- 8.2.2. Forensic Laboratories
- 8.2.3. Hospitals and Diagnostic Centers
- 8.2.4. Pharmaceutical and Biotechnology Companies
- 8.2.5. Research Laboratories and Academic Institutes
9. Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By Region, 2019-2030 (USD Million)
- 9.1. North America
- 9.1.1. United States
- 9.1.2. Canada
- 9.1.3. Mexico
- 9.2. Europe
- 9.2.1. Germany
- 9.2.2. United Kingdom
- 9.2.3. France
- 9.2.4. Italy
- 9.2.5. Spain
- 9.2.6. Rest of Europe
- 9.3. Asia-Pacific
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. India
- 9.3.4. Australia
- 9.3.5. South Korea
- 9.3.6. Rest of Asia-Pacific
- 9.4. South America
- 9.5. Middle East & Africa
- 9.5.1. Kingdom of Saudi Arabia
- 9.5.2. United Arab Emirates
- 9.5.3. Rest of Middle East & Africa
10. Company Profiles
- 10.1. Abbott Laboratories
- 10.1.1. Company details
- 10.1.2. Financial outlook
- 10.1.3. Product summary
- 10.1.4. Recent developments
- 10.2. Agilent Technologies
- 10.2.1. Company details
- 10.2.2. Financial outlook
- 10.2.3. Product summary
- 10.2.4. Recent developments
- 10.3. Analytik Jena AG
- 10.3.1. Company details
- 10.3.2. Financial outlook
- 10.3.3. Product summary
- 10.3.4. Recent developments
- 10.4. Becton Dikinson and Company
- 10.4.1. Company details
- 10.4.2. Financial outlook
- 10.4.3. Product summary
- 10.4.4. Recent developments
- 10.5. bioMerieux SA
- 10.5.1. Company details
- 10.5.2. Financial outlook
- 10.5.3. Product summary
- 10.5.4. Recent developments
- 10.6. Bioneer
- 10.6.1. Company details
- 10.6.2. Financial outlook
- 10.6.3. Product summary
- 10.6.4. Recent developments
- 10.7. Bio-Rad Laboratories Inc.
- 10.7.1. Company details
- 10.7.2. Financial outlook
- 10.7.3. Product summary
- 10.7.4. Recent developments
- 10.8. Danaher Corporation
- 10.8.1. Company details
- 10.8.2. Financial outlook
- 10.8.3. Product summary
- 10.8.4. Recent developments
- 10.9. ELITech Group
- 10.9.1. Company details
- 10.9.2. Financial outlook
- 10.9.3. Product summary
- 10.9.4. Recent developments
- 10.10. Enzo Life Sciences, Inc.
- 10.10.1. Company details
- 10.10.2. Financial outlook
- 10.10.3. Product summary
- 10.10.4. Recent developments
- 10.11. Eppendorf
- 10.11.1. Company details
- 10.11.2. Financial outlook
- 10.11.3. Product summary
- 10.11.4. Recent developments
- 10.12. F. Hoffmann-La Roche, Ltd.
- 10.12.1. Company details
- 10.12.2. Financial outlook
- 10.12.3. Product summary
- 10.12.4. Recent developments
- 10.13. Fluidigm Corporation
- 10.13.1. Company details
- 10.13.2. Financial outlook
- 10.13.3. Product summary
- 10.13.4. Recent developments
- 10.14. Merck KGaA
- 10.14.1. Company details
- 10.14.2. Financial outlook
- 10.14.3. Product summary
- 10.14.4. Recent developments
- 10.15. Meridian Bioscience
- 10.15.1. Company details
- 10.15.2. Financial outlook
- 10.15.3. Product summary
- 10.15.4. Recent developments
- 10.16. Promega Corporation
- 10.16.1. Company details
- 10.16.2. Financial outlook
- 10.16.3. Product summary
- 10.16.4. Recent developments
- 10.17. QIAGEN N.V.
- 10.17.1. Company details
- 10.17.2. Financial outlook
- 10.17.3. Product summary
- 10.17.4. Recent developments
- 10.18. Quidel Corporation
- 10.18.1. Company details
- 10.18.2. Financial outlook
- 10.18.3. Product summary
- 10.18.4. Recent developments
- 10.19. Takara Bio
- 10.19.1. Company details
- 10.19.2. Financial outlook
- 10.19.3. Product summary
- 10.19.4. Recent developments
- 10.20. Thermo Fisher Scientific
- 10.20.1. Company details
- 10.20.2. Financial outlook
- 10.20.3. Product summary
- 10.20.4. Recent developments
